Federal distribution channels including mass vaccination centers will temporarily stop using the drug
Washington— The United States today proposed to “suspend” the use of the coronavirus vaccine developed by Johnson & Johnson to investigate reports of potentially dangerous blood clots.
The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) said in a joint statement that they are investigating blood clots detected in six women within a few days of vaccination, combined with a reduction in platelet counts. In the United States, more than 6.8 million doses of J&J vaccine have been administered, and this is one application.
Federal distribution channels, including mass vaccination centers, will temporarily stop using the drug, and states and other suppliers are expected to do the same.
The other two vaccines, Moderna and Pfizer, account for the vast majority of vaccines vaccinated in the United States and are not affected by the hole.
The CDC’s Immunization Practice Advisory Committee will meet on Wednesday to study these cases. The FDA has begun its own investigation.
CDC Deputy Director Dr. Anne Schuchat and Director of the FDA Biological Evaluation and Research Center Peter Marks said: “We recommend that you suspend the use of the vaccine as a preventive measure until the entire process is completed.” Joint statement.
These agencies recommend that those who have received the Johnson & Johnson vaccine and experience headache, abdominal pain, leg pain or difficulty breathing within three weeks of the injection contact their doctor.
Relevant departments stated that they hope to train vaccine manufacturers and healthcare professionals on the “single treatment” of these blood clots.
Johnson & Johnson claims to be aware of blood clots, but insists that it has not clearly established a link with its vaccine.
The company said in a statement: “We are already aware of thromboembolic events related to the anti-COVID-19 vaccine, including some thrombocytopenia.” He added: “So far, there has been no difference between these abnormal events and the vaccine. Establish a clear cause and effect relationship.”
The FDA held a grand ceremony in late February to remove the J&J vaccine as an emergency resource, hoping that by requiring a single dose and relatively easy storage conditions, it will promote vaccination campaigns nationwide. However, due to delays and errors at a contractor’s factory in Baltimore, the vaccine only accounts for a small percentage of the two vaccines in the United States.